Health Care [ 6/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy.
The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | 0.68 Increased by +106.06% | 0.39 Increased by +74.36% |
| May 6, 25 | 0.68 Increased by +257.89% | 0.53 Increased by +29.11% |
| Feb 26, 25 | 0.70 Increased by +125.81% | 0.32 Increased by +118.75% |
| Nov 6, 24 | 0.35 Increased by +220.69% | 0.30 Increased by +16.67% |
| Aug 7, 24 | 0.33 Decreased by -37.74% | 0.26 Increased by +26.92% |
| May 8, 24 | 0.19 Decreased by -26.92% | 0.17 Increased by +11.76% |
| Feb 28, 24 | 0.31 Increased by +40.91% | 0.27 Increased by +14.81% |
| Nov 8, 23 | -0.29 Decreased by -245.00% | -0.28 Decreased by -3.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 146.56 M Increased by +19.44% | 52.11 M Increased by +27.73% | Increased by +35.55% Increased by +6.95% |
| Mar 31, 25 | 141.42 M Increased by +43.56% | 56.74 M Increased by +143.77% | Increased by +40.12% Increased by +69.80% |
| Dec 31, 24 | 141.82 M Increased by +28.26% | 55.94 M Increased by +60.53% | Increased by +39.44% Increased by +25.16% |
| Sep 30, 24 | 128.69 M Increased by +25.33% | 43.88 M Increased by +242.65% | Increased by +34.10% Increased by +213.82% |
| Jun 30, 24 | 122.71 M Increased by +23.23% | 40.79 M Increased by +8.03% | Increased by +33.24% Decreased by -12.33% |
| Mar 31, 24 | 98.51 M Increased by +15.40% | 23.27 M Decreased by -21.28% | Increased by +23.63% Decreased by -31.79% |
| Dec 31, 23 | 110.57 M Increased by +81.98% | 34.84 M Increased by +36.80% | Increased by +31.51% Decreased by -24.83% |
| Sep 30, 23 | 102.69 M Increased by +79.39% | -30.76 M Decreased by -235.24% | Decreased by -29.96% Decreased by -175.39% |